Novo Nordisk A/S — Danish pharma leader in diabetes and obesity drugs (Ozempic, Wegovy).
News
13- NVO▲Novo Nordisk expects to launch Wegovy pill in Germany in September4d
- NVO▼Novo Nordisk Q2 operating profit negatively affected by US 340B rebate provision reversal×24d
- NVO▲Novo Nordisk raises outlook, driven by improved GLP-1 sales expectations×24d
- NVO▼Novo Nordisk to take Q3 non-cash impairment after ZEUS outcome9d
| Venues | Issuers | Symbol | Mark | Volume 24h | Liquidity | Vol % | Contract |
|---|---|---|---|---|---|---|---|
 Binance Alpha |  | NVOon | 47.21 | — | — | — | 0x08a5…28a8 |
 Ondo Markets | | NVO | — | — | — | — | 0x2815…93e3 |
 Solana |  | XsfAzP…87S57n | 45.95 | — | $124.03 | — | XsfAzP…S57n |